At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Naloxone Auto-injector as a Universal Precaution for Patients With Opioid Use Disorder
In Brief
A clinical study evaluating Naloxone Auto-Injector for Opiate Antagonist Overdose and Opioid-Related Disorders. Completed, enrolled 395 participants across 1 site.
Detailed Summary
The purpose of this pilot-study is to to distribute naloxone auto-injector in a "Universal Precaution" manner to patients with opioid substance use disorder. The objectives are to decrease the number of fatal and nonfatal overdose deaths, to examine and understand the risk factors for serious opioid toxicity and overdose, and to evaluate the unintentional opioid overdose risk utilizing an evidence-based screening questionnaire.
Study Details
Timeline
Interventions
Naloxone auto-injector is FDA approved and labeled for use by family members or caregivers for emergency therapy and rescue wherever opioids are present. Bystanders of patient are able to provide naloxone when drug overdose occurs.